Indigenous men were at higher risk of developing PCa metastases than non-Indigenous men . Men in Indigenous communities were less likely to have PSA testing performed than men outside of Indigenous community .
Tag: Prostate Cancer
Disparities in prostate cancer screening, diagnoses, management, and outcomes between Indigenous and non‐Indigenous men in a universal health care system
Indigenous men were at higher risk of developing PCa metastases than non-Indigenous men . Men in Indigenous communities were less likely to have PSA testing performed than men outside of Indigenous community .
Outcomes after definitive radiation therapy for localized prostate cancer in a national health care delivery system
Abstract Purpose Accurate information regarding real-world outcomes after contemporary radiation therapy for localized prostate cancer is important for shared decision-making. Clinically relevant end points at 10 years among men treated within a national health care delivery system were examined. Methods National administrative, cancer registry, and electronic health record data were used for patients undergoing definitive radiation… Continue reading Outcomes after definitive radiation therapy for localized prostate cancer in a national health care delivery system
Outcomes after definitive radiation therapy for localized prostate cancer in a national health care delivery system
Clinically relevant end points at 10 years among men treated within a national health care delivery system were examined . Median age at diagnosis was 65 years and median follow-up was 8.7 years . Most had intermediate (42%) and high-risk (33%) disease, with 40% receiving androgen deprivation therapy as part of initial therapy .
Top advances of the year: Genitourinary cancer
There is now greater clarity on the role of the use of immunotherapies in renal cell carcinoma . Antibody drug conjugates have continued to show activity in urothelial cancer with promising clinical outcomes . Data are also discussed regarding intensification for front-line therapy of metastatic castrate sensitive prostate cancer .
Top advances of the year: Genitourinary cancer
There is now greater clarity on the role of the use of immunotherapies in renal cell carcinoma . Antibody drug conjugates have continued to show activity in urothelial cancer with promising clinical outcomes . Data are also discussed regarding intensification for front-line therapy of metastatic castrate sensitive prostate cancer .
Differential treatment effect between younger and older adults for new cancer therapies in solid tumors supporting US Food and Drug Administration approval between 2010 and 2021
The authors quantified how treatment effects differ between older and younger patients in oncology registration trials . The primary outcome was differential treatment effect by age for progression-free survival and overall survival . Only 7% of end points showed a statistically significant interaction between outcome and age group . There were no changes in the… Continue reading Differential treatment effect between younger and older adults for new cancer therapies in solid tumors supporting US Food and Drug Administration approval between 2010 and 2021
Differential treatment effect between younger and older adults for new cancer therapies in solid tumors supporting US Food and Drug Administration approval between 2010 and 2021
Abstract Background Over one half of cancer diagnoses occur in patients aged 65 and older. The authors quantified how treatment effects differ between older and younger patients in oncology registration trials. Methods The authors performed a retrospective cohort study of registration trials supporting US Food and Drug Administration approval of cancer drugs (from January 2010… Continue reading Differential treatment effect between younger and older adults for new cancer therapies in solid tumors supporting US Food and Drug Administration approval between 2010 and 2021
The cost burden of metastatic prostate cancer in the US populations covered by employer‐sponsored health insurance
Abstract Background Recent advancements in the clinical management of metastatic prostate cancer include several costly therapies and diagnostic tests. The objective of this study was to provide updated information on the cost to payers attributable to metastatic prostate cancer among men aged 18 to 64 years with employer-sponsored health plans and men aged 18 years… Continue reading The cost burden of metastatic prostate cancer in the US populations covered by employer‐sponsored health insurance
The cost burden of metastatic prostate cancer in the US populations covered by employer‐sponsored health insurance
The cost burden attributable to metastatic prostate cancer exceeds $55,000 per person-year among men with employer-sponsored health insurance . The authors used Merative MarketScan commercial and Medicare supplemental data for 2009–2019 . These estimates can improve the precision of value assessments of clinical and policy approaches to the prevention, screening, and treatment of prostate cancer in the… Continue reading The cost burden of metastatic prostate cancer in the US populations covered by employer‐sponsored health insurance